UK – NICE’s decision not to approve Zytiga ‘frustrating’, says ICR

The National Institute of Health and Care Excellence (NICE) has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.

In June 2020, NICE initially rejected Zytiga (abiraterone) as a first-line treatment for newly diagnosed, advanced prostate cancer.

Following this initial rejection, NICE announced that it would reconsider its decision. However, the cost-effectiveness watchdog has now concluded that it will not recommend Zytiga…